English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

D an array of medications available in the United States to treat patients with type 2 diabetes mellitus (T2DM), physicians still have not achieved optimal control of this disease. In the present supplement to JAOA— The Journal of the American Osteopathic Association, we look at 3 contributing factors to this phenomenon. Mark D. Baldwin, DO, addresses the topic of cardiovascular risk associated with diabetes mellitus. Steven H. Barag, DO, discusses the advantages of using insulin early in the treatment of patients with T2DM. Finally, Alan J. Garber, MD, PhD, explores incretin-based agents, including their unique nonglycemic benefits. Dr Baldwin provides evidence to support the claim that diabetes mellitus is a cardiovascular risk equivalent. Furthermore, he reviews the outcomes of the major intensive glucose-lowering trials that evaluated cardiovascular outcomes— the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial,1 the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial,2 and the Veterans Affairs Diabetes Trial (VADT).3 Dr Baldwin then balances these findings with the longterm outcomes from the epidemiologic follow-ups of the United Kingdom Prospective Diabetes Study (UKPDS)4 and the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study.5 He reviews glucose-lowering effects, nonglycemic benefits, and risks of available agents and discusses how these agents contribute to cardiovascular risk modification. Dr Barag covers various aspects of the early introduction of insulin in T2DM management. He offers compelling evidence of the benefit of this approach. He also explores patient and physician barriers to insulin use, noting how a pro active physician can overcome these barriers. Finally, Dr Barag provides physicians with a number of treatment algorithms6-8 to initiate and proactively titrate insulin doses with the goal of achieving glycemic control quickly and safely. Dr Garber reviews the pathophysiologic mechanisms of the incretin system in the development of T2DM. He further examines how to achieve glucose control while maintaining or even advancing other metabolic benefits. He provides an overview of glucagon-like peptide-1, or GLP-1, receptor agonists, including their effects on glucose levels, weight, and blood pressure. Dr Garber also reviews data on dipeptidyl peptidase-4, or DPP-4, inhibitors, an oral class of agents that

Optimizing Treatment for Patients With Diabetes Mellitus: Glycemic and Nonglycemic Effects